AI in Healthcare 2025

Tern plc

The year 2025 marked a significant shift in the integration of artificial intelligence into healthcare, as the technology moved from experimental phases into active use across clinical and commercial settings. AI, once viewed as a long-term prospect, began delivering practical benefits, with healthcare organisations adopting it to streamline operations, enhance patient communication and improve medical outcomes.

Throughout the year, generative AI was deployed more widely in hospitals, clinics and pharmaceutical companies. Clinical teams used it to produce care plans and patient notes in real time, reducing time spent on documentation and allowing more focus on decision-making and patient care. Predictive AI was applied to flag potential hospital readmissions and other risks before they materialised, contributing to efficiency gains and better patient outcomes. At the same time, AI-generated, multi-language patient education materials helped address gaps in communication, particularly for underserved populations.

In the pharmaceutical and healthcare marketing sectors, data intelligence and targeting technologies helped refine how companies engaged with both clinicians and patients. Rather than relying on broad messaging, marketers used AI-driven insights to tailor communications more precisely, increasing engagement and improving return on investment.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc reports 2025 results and outlines portfolio value strategy

Tern plc has reported audited annual results, outlined portfolio developments and convened a General Meeting for 9 July 2026.

Device Authority targets enterprise IoT security demand through Xalient partnership

Device Authority has partnered with Xalient to bring KeyScaler into managed enterprise security services, strengthening its position in scalable IoT and OT device identity management.

Talking Medicines targets a clearer view of GLP-1 and cancer care demand

Talking Medicines is showing why real-world healthcare conversations matter for investors tracking GLP-1, oncology and the next stage of life sciences market positioning.

GLP-1 cancer signals add a new investor angle

Early oncology signals from ASCO 2026 add a new investor angle to the GLP-1 story, with further research needed before clinical or commercial conclusions can be drawn.

Device Authority expands enterprise reach through IoT security partnership

Device Authority’s partnership with Xalient strengthens its enterprise IoT security positioning as regulated industries look for scalable, automated ways to manage connected device risk.

Pharma engagement shifts from reach to relevance

Pharma engagement is moving from broad reach to relevant messaging across connected patient journeys.

Search